XTENT, which is developing a treatment for coronary artery disease, announced on Thursday that it plans to offer 4.7 million shares in its IPO. The proposed range for the deal is $16-$18, which gives the company a proposed market cap of $415 million. Piper Jaffray is managing the deal and has yet to announce timing.
